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Abstract
Objective—No clear consensus has been reached on the PTPN22 R620W polymorphism and 
anti-neutrophil cytoplasmic antibody (ANCA) disease, especially when stratified by ANCA 
specificity and disease phenotypes.
Methods—A metaanalysis was conducted on the PTPN22 R620W polymorphism across 4 
studies in 1399 white patients with ANCA disease and 9934 normal control subjects.
Results—Overall, metaanalysis showed a statistically significant association between the A 
allele and ANCA disease in all subjects (OR 1.44, 95% CI 1.26–1.64, p < 0.00001), and 
stratification by disease category indicated the A allele was associated with granulomatosis with 
polyangiitis (Wegener’s; GPA; OR 1.72, 95% CI 1.35–2.20, p < 0.0001) and microscopic 
polyangiitis (MPA; OR 1.53, 95% CI 1.08–2.15, p = 0.02) as compared to controls. However, 
when stratified by ANCA specificity, the association of the A allele was statistically evident 
among those with proteinase 3 (PR3) ANCA disease (OR 1.74, 95% CI 1.25–2.430, p = 0.001), 
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with the same trend but not statistically associated with myeloperoxidase ANCA disease (OR 
1.94, 95% CI 0.64–5.85, p = 0.24). The marked associations were also demonstrated between this 
allele with lung (OR 1.69, 95% CI 1.21–2.36, p = 0.002), ENT (OR 2.03, 95% CI 1.45–2.84, p < 
0.0001), skin (OR 2.55, 95% CI 1.69–3.84, p < 0.0001), and peripheral neuropathy involvement 
(OR 2.12, 95% CI 1.39–3.22, p = 0.0005).
Conclusion—The PTPN22 620W allele confers susceptibility to the occurrence and 
development of ANCA disease in whites, with specific evidence among subsets with GPA, MPA, 
and PR3 ANCA. (J Rheumatol First Release Dec 1 2014; doi:10.3899/jrheum.131430)
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Antineutrophil cytoplasmic antibody (ANCA) disease is characterized by necrotizing 
inflammation of small blood vessels. ANCA is categorized into several disease groups, 
including granulomatosis with polyangiitis (Wegener’s; GPA), microscopic polyangiitis 
(MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), as proposed by the 
Chapel Hill Consensus Conference1.
The cause of ANCA disease is not clear. Although both environmental factors2 and 
epigenetic changes3 have been implicated, the molecular genetics of ANCA contributes 
significantly to the pathogenesis of the disease4. In 2004, a single nucleotide polymorphism 
(SNP) in the protein tyrosine phosphatase nonreceptor 22 (PTPN22) gene (R620W, 
rs2476601, C1858T) was identified; it caused a protein modification, which disrupted the 
regulatory domain of the phosphatase, conferring a gain-of-function phenotype. It has been 
demonstrated that this genetic variant is associated with numerous other autoimmune 
diseases including type 1 diabetes5,6,7,8,9, rheumatoid arthritis10,11,12,13,14,15, and systemic 
lupus erythematosus16,17,18. Later this genetic variant was demonstrated to be linked with 
ANCA disease in 4 studies19,20,21,22. However, as a rare autoimmune disease, the number of 
patients was relatively small within each individual study. Further, a genome-wide 
association study (GWAS) suggested that proteinase 3 (PR3) and myeloperoxidase (MPO) 
had distinct genetic origins4. The published genetic association results for the PTPN22 
R620W polymorphism are controversial and inconclusive when the disease is stratified by 
clinical phenotype and ANCA specificity, a practice that might be due to small sample sizes, 
low statistical power, and/or clinical heterogeneity. Therefore, to overcome the limitations 
of individual studies and resolve inconsistencies, we turned to metaanalysis in the subgroup 
of ANCA disease. We investigated whether the PTPN22 R620W polymorphism contributes 
to the susceptibility of ANCA diseases and their subtypes using a metaanalysis approach.
MATERIALS AND METHODS
Identification and eligibility of relevant studies
To identify all studies that examined the association of PTPN22 R620W (rs 2476601) 
polymorphism with ANCA disease, we performed a systematic, computerized literature 
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search of the PubMed database, Embase, and the Cochrane library (up to August 2013) 
using the following various combinations of keywords and subject terms: “tyrosine 
phosphatase non-receptor 22” OR “PTPN22”, “polymorphism” OR “polymorphisms” and 
“anti-neutrophil cytoplasmic antibody” OR “ANCA” OR “AAV” (ANCA-associated 
vasculitis).
We also retrieved additional studies through the MEDLINE option “related articles.” Search 
results were limited to research articles in English and studies on human subjects without 
country restrictions. The full text of the retrieved articles was scrutinized to decide whether 
information on the topic of interest was included. Studies included in the metaanalysis had 
to meet all the following criteria: (1) use of cases compared to unrelated controls (either 
retrospective or cross-sectional), (2) available genotype frequency, (3) a genotype 
distribution of the control population consistent with Hardy Weinberg equilibrium (HWE). 
All the patients met the criteria of the Chapel Hill consensus conference definition for GPA, 
MPA, and EGPA1.
Data extraction
To extract the information needed, all articles were separately collected and reviewed by 2 
independent investigators (YC, KL) who checked for any discordance and reached a 
consensus. If they could not come to an agreement, a third investigator adjudicated the 
disagreements. The following information was collected from the studies on the genotype of 
PTPN22 R620W: first author, year of publication, full citation information, country, sample 
sizes of cases and controls, genotype numbers, allele frequency in both cases and controls, 
and p values of HWE in controls. Allele frequency in cases by disease category and ANCA 
specificity were also collected.
Statistical analysis
The strength of the association of Arg620Trp (R620W) with ANCA disease was measured 
by OR compared to controls, with corresponding 95% CI calculated according to the method 
of Woolf23. We examined the association between the W allele of PTPN22 R620W and 
ANCA disease risk (A vs G), the dominant genetic model (AA + GA vs GG), the recessive 
genetic model (AA vs GA + GG), and homozygote comparison (AA vs GG). In our study, 2 
models of metaanalysis were used for dichotomous outcomes in the Review-Manager 5.2 
software: the fixed-effects model and the random-effects model. The fixed-effects model 
used the Peto Mantel–Haenszel method, which assumes that studies are sampled from 
populations with the same effect size, and adjusts the study weights according to the in-
study variance. The random-effects model used the Der Simonian and Laird’s method, 
which assumes that the studies are taken from populations with varying effect sizes, and 
calculates the study weights both from in-study and between-study variances, considering 
the extent of variation or heterogeneity. We performed a chi squared Q statistic test to assess 
between study heterogeneity24. Heterogeneity was considered significant for p < 0.10 
because of the low power of the statistic. The inconsistency index I2 was also calculated to 
evaluate the variation that was caused by heterogeneity rather than by chance, and higher 
values of the index indicated the existence of heterogeneity25. A p value > 0.10 for the Q-
test indicates a lack of heterogeneity among studies, and the pooled OR estimate of each 
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study was calculated with the fixed-effects model26. Otherwise, the random-effects model 
was used27. The significance of the pooled OR was determined by the Z test and a p value of 
< 0.05 was considered significant. The same methods were used comparing subgroups based 
on ANCA specificity, disease specificity, and organ involvement to controls.
In addition, an estimate of potential publication bias was carried out by the funnel plot, with 
an asymmetric plot indicating possible publication bias. HWE was tested by the chi-square 
test for goodness-of-fit based on a Web program (www.ihg.gsf.de/cgi-bin/hw/hwa1.pl). 
Analyses were performed using the software Review-Manager 5.2. All p values were 2-
sided.
RESULTS
Description of studies identified in metaanalysis
Figure 1 shows the flow chart summarizing the process of study selection and reasons for 
exclusion. The GWAS mentioned in introduction was not included because the PTPN22 
R620W allele was not included in the GWAS study. Six relevant studies were identified that 
examined the association between polymorphisms of PTPN22 R620W and ANCA 
vasculitis. Two studies were excluded because they were metaanalyses used to determine the 
association between PTPN22 R620W and vasculitis, including Takayasu arteritis, Henoch-
Schönlein purpura, Behçet disease, giant cell arteritis, and ANCA-associated27 or other 
autoimmune diseases28. Thus, 4 studies met the inclusion criteria19,20,21,22 and involved a 
total of 1399 patients and 9934 controls. There was 1 study each in Germany, the United 
Kingdom, Italy, and the United States. All cases and controls involved in these studies were 
white. The pooled overall frequencies of the A allele were 11.62% and 9.11% in ANCA 
cases and in controls, respectively. Detailed information on eligible studies, sample size, the 
distribution of R620W genotypes, A allele frequencies of cases and controls, and p values of 
HWE in controls are described in Tables 1a and 1b.
PTPN22 R620W polymorphism conferred susceptibility to ANCA disease
For each study, we investigated the association between the PTPN22 R620W 
polymorphisms and ANCA disease risk, assuming different inheritance models of the 620W 
allele (Table 2). Overall, when all the eligible studies were pooled into the metaanalysis, 
significant associations between PTPN22 R620W polymorphism and ANCA susceptibility 
were observed in all genetic models, including allele comparison (A vs G: p < 0.00001, OR 
1.44, 95% CI 1.26–1.64, Pheterogeneity 0.87; Figure 2a), dominant genetic model (AA + GA 
vs GG: p < 0.00001, OR 1.48, 95% CI 1.28–1.70, Pheterogeneity 0.89; Figure 2b), recessive 
genetic model (AA vs GA + GG: p = 0.03, OR 1.80, 95% CI 1.07–3.02, Pheterogeneity 0.92; 
Figure 2c), and homozygote comparisn (AA vs GG: p = 0.01, OR 1.94, 95% CI 1.15–3.25, 
Pheterogeneity 0.91; Figure 2d).
Significant association identified in the PTPN22 R620W polymorphism with both GPA and 
MPA
When all the available data were pooled into the metaanalysis (Table 2), a significant 
association between PTPN22 R620W polymorphism and GPA susceptibility was observed 
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in allele comparison (A vs G p < 0.0001, OR 1.72, 95% CI 1.35–2.20, Pheterogeneity 0.87; 
Figure 3a). A similar result was also observed in the MPA subgroup (A vs G: p = 0.02, OR 
1.53, 95% CI 1.08–2.15, Pheterogeneity 0.86; Figure 3b).
PTPN22 R620W polymorphism was significantly correlated with PR3-ANCA serotype, but 
inconclusive with the MPO-ANCA serotype
We pooled the available data into the metaanalysis and found that there was a significant 
association between PTPN22 R620W polymorphism and PR3-ANCA in allele comparison 
(A vs G: p = 0.001, OR 1.74, 95% CI 1.25–2.43, Pheterogeneity 0.74; Figure 3c). However, 
carriage of this variant allele was inconclusive with MPO-ANCA serotype in allele 
comparison, with a large association but also a wide CI that crossed and equaled OR (1.0; A 
VS G: p = 0.24, OR 1.94, 95% CI 0.64–5.85, Pheterogeneity 0.04; Table 2, Figure 3d).
PTPN22 R620W polymorphism association with organ involvement
Further analysis of this polymorphism focused on its association with organ involvement. 
Organ involvement in the patients with AAV was assessed by physical examination, routine 
laboratory tests, and a standardized set of imaging studies. Two available datasets from Italy 
and the United States were pooled for this analysis. The 620W allele was significantly 
associated with lung involvement (A vs G: p = 0.002, OR 1.69, 95% CI 1.21–2.36, 
Pheterogeneity 0.35), ENT involvement (A vs G: p < 0.0001, OR 2.03, 95% CI 1.45–2.84, 
Pheterogeneity 0.90), skin involvement (A vs G: p < 0.00001, OR 2.55, 95% CI 1.69–3.84, 
Pheterogeneity 0.20) and peripheral neuropathy involvement (A vs G: p = 0.0005, OR 2.12, 
95% CI 1.39–3.22, Pheterogeneity 0.68). This allele was positively but not statistically 
associated with kidney involvement (A vs G: p = 0.20, OR 1.44, 95% CI 0.82–2.53, 
Pheterogeneity 0.09;Table 3).
Heterogeneity and publication bias
The shape of the funnel plot did not reveal any evidence of obvious asymmetry, and no 
evidence of publication bias was found in the metaanalysis (Appendix 1).
DISCUSSION
This is the largest systematic review to date, to our knowledge, investigating the association 
between PTPN22 R620W polymorphism and ANCA disease. Compared with the 
metaanalysis of 3 studies by Lee, et al27, our metaanalysis included 4 studies with 1399 
patients and 9934 controls. Our study also included stratified metaanalyses based on ANCA 
type and disease specificity. Consistent with the former metaanalysis, we observed a 
significant association between the PTPN22 R620W polymorphism and susceptibility to 
ANCA disease. The GWAS by Lyons, et al did not find the association between PTPN22 
and ANCA disease4. However, they did not directly type rs2476601 in the GWAS study but 
instead typed rs6679677. Perhaps the 2 SNP could not tag each other perfectly. We had a 
large number of patients enrolled in our study and conducted further subgroup analysis, 
which showed the association of the disease-associated allele skewed toward PR3-ANCA 
disease, and suggested but did not detect an association for MPO-ANCA disease. 
Considering the small sample size and limited statistical power, future studies based on 
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large-scale investigation are needed to further validate the association of PTPN22 620W 
polymorphism and MPO-ANCA disease in a white population.
Our metaanalysis reinforces the strength of the association between the R620W and 
susceptibility to both GPA and MPA. GPA and MPA are 2 distinct yet overlapping 
syndromes of AAV. It has been demonstrated that the strongest genetic associations were 
with the antigenic specificity of ANCA, rather than with the clinical syndrome4. The results 
of our metaanalysis were consistent with this conclusion. However, our results should be 
interpreted with caution because only 2 studies provided data in the subgroup of ANCA 
specificity. In addition, the results of the 2 above studies21,22 were positive for PR3-ANCA 
disease and neither was statistically significant for MPO-ANCA disease. This might be 
explained by the geographical and genetic factors involved in the pathogenesis of ANCA 
disease. Prevalence of ANCA type varies across geographic regions, with PR3-ANCA being 
more common in northern European populations and MPO-ANCA more common in 
southern European countries29,30,31. US cohorts suggested that PR3-ANCA was more 
prevalent in whites than in African Americans32. Additionally, MPO-ANCA is predominant 
in Asian countries33,34. The geographic distribution of this variant allele is highest in 
countries where PR3-ANCA is predominant. The allele is nearly absent in African American 
and Asian populations35.
In the present metaanalysis, the genotypic-phenotypic associations were also investigated. In 
the US study22, the A allele was particularly associated with lung, ENT, skin, and peripheral 
nervous system involvement. The Italian group21 instead found that this allele was enriched 
predominantly in GPA patients with ENT involvement, lung involvement, and skin lesions 
other than purpura. Our results seem to point to a particular association between the PTPN22 
SNP and a PR3-ANCA disease pattern. It has been noted that patients with the most 
compelling evidence for necrotizing granulomatous inflammation are most likely to have 
PR3-ANCA36. Skin lesions and peripheral neuropathy may be granulomatous and are 
common phenotypes in PR3-ANCA disease37. Interestingly, PTPN22 is thought to be 
involved in granuloma formation38.
The results of our metaanalysis should be interpreted within the context of its limitations. 
First, we focused only on papers published in the English language, so some local literature 
biases were inevitable. Second, only a small number of studies were conducted on the 
subgroup of ANCA disease, which may mean that our investigation was underpowered. 
Third, our ethnic-specific metaanalysis was performed using data from white patients, and 
thus our results are only applicable to this ethnic group. Further studies are required in 
different ethnic populations, because the prevalence of the PTPN22 R620W polymorphism 
is ethnicity-dependent. Fourth, the results for publication bias should be interpreted with 
caution, given the relatively small number of available studies.
Our metaanalysis demonstrates that the PTPN22 R620W polymorphism confers 
susceptibility to ANCA disease in whites. In contrast, carriage of this variant allele was 
inconclusive with the MPO-ANCA serotype, which needs to be studied in larger samples.
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Flow chart of selection of studies and specific reasons for exclusion from the metaanalysis.
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Association between PTPN22 R620W polymorphism and antineutrophil cytoplasmic 
antibodies (ANCA) disease risk. Figure 2a shows the association between PTPN22 R620W 
polymorphism and ANCA disease in allele comparison (A vs G). Figure 2b shows the 
association between R620W polymorphism and ANCA disease under the dominant genetic 
model (AA + GA vs GG). Figure 2c shows the association between R620W polymorphism 
and ANCA disease under recessive genetic model (AA vs GA + GG). Figure 2d shows the 
association between R620W polymorphism and ANCA disease in homozygote comparison 
(AA vs GG). AVV: ANCA-associated vasculitis; M-H: Mantel-Haenszel test.
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Association between PTPN22 R620W polymorphism and antineutrophil cytoplasmic 
antibodies (ANCA) disease stratified by disease phenotype and ANCA serology. Figure 3a 
shows the association between PTPN22 R620W polymorphism and granulomatosis with 
polyangiitis (GPA) in allele comparison (A vs G). Figure 3b shows the association between 
PTPN22 R620W polymorphism and microscopic polyangiitis (MPA) in allele comparison 
(A vs G). Figure 3c shows the association between PTPN22 R620W polymorphism and 
proteinase 3 (PR3)-ANCA disease in allele comparison (A vs G). Figure 3d shows the 
association between PTPN22 R620W polymorphism and myeloperoxidase (MPO)-ANCA 
disease in allele comparison (A vs G). M-H: Mantel-Haenszel test.
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Funnel plot for allele comparison.
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Table 1B Characteristics of the individual studies stratified by disease, ANCA type, and organ involvement.
Subgroup Sample Sizes Allele for Cases Allele for Controls
Case Control Total G A G A
GPA 416 2522 2938 725 107 4672 372
MPA 212 2123 2335 382 42 3954 292
PR3 200 2123 2323 355 45 3954 292
MPO 125 2123 2248 223 27 3954 292
Lung 202 2123 2325 360 44 3954 292
ENT 188 2123 2311 331 45 3954 292
Skin 92 2123 2215 154 30 3954 292
Peripheral neuropathy 98 2123 2221 168 28 3954 292
Kidney 278 2123 2401 504 52 3954 292
Jagiello, et al (2005), Martorana, et al (2012), Cao, et al (2012) were available for GPA subgroup. Martorana and Cao were available for MPA, 
PR3, MPO, lung, ENT, skin, peripheral neuropathy, and kidney subgroups. HWE: Hardy-Weinberg equilibrium; ANCA: antineutrophil 
cytoplasmic antibody; GPA: granulomatosis with polyangiitis (Wegener’s); MPA: microscopic polyangiitis; PR3: proteinase 3; MPO: 
myeloperoxidase.
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Table 2





Test of Heterogeneity Test of Association
Model I2 (%) p OR 95% CI p
A vs G AAV 4 F 0 0.87 1.44 1.26–1.64 2.27 × 10−5
GPA 3 F 0 0.87 1.72 1.35–2.20 1.25 × 10−7
MPA 2 F 0 0.86 1.53 1.08–2.15 0.02
PR3 2 F 0 0.74 1.74 1.25–2.43 0.001
MPO 2 R 77 0.04 1.94 0.64–5.85 0.24
AA + GA vs GG AAV 4 F 0 0.89 1.48 1.28–1.70 5.10 × 10−5
AA vs GA + GG AAV 4 F 0 0.92 1.80 1.07–3.02 0.03
AA vs GG AAV 4 F 0 0.91 1.94 1.15–3.25 0.01
AAV: antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; 
MPO: myeloperoxidase; PR3: proteinase 3; F: fixed effects model; R: random effects model.
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Table 3
Metaanalysis of the association between the PTPN22 R620W polymorphism and organ involvement.
Genotype Contrasts Organ
Involvement
Ref No. Test of Heterogeneity Test of Association
Model I2 (%) p OR 95% CI p
A vs G Lung 2 F 0 0.35 1.69 1.21–2.36 0.002
ENT 2 F 0 0.90 2.03 1.45–2.84 3.33 × 10−4
Skin 2 F 0 0.20 2.55 1.69–3.83 3.31 × 10−6
Peripheral neuropathy 2 F 0 0.68 2.12 1.39–3.22 0.0005
Kidney 2 R 66 0.09 1.44 0.82-2.53 0.20
F: fixed effects model; R: random effects model.
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